Baseline and early natural history report. The Central Vein Occlusion Study.
Baseline and early natural history report. The Central Vein Occlusion Study.
复制标题
DOI:
--
复制
发表时间:
1993
影响因子:
--
通讯作者:
J. Clarkson;E. Chuang;D. Gass;M. Pedroso;T. Cubillas;E. S. Duria;D. Hess;I. Rams;A. Gutierrez;P. Kiès;N. Muniz;M. Pall;C. Pappas;D. Finkelstein;A. Patz;D. Rytel;J. Belt;D. Cain;A. Hillis
中科院分区:
文献类型:
--
作者:
J. Clarkson;E. Chuang;D. Gass;M. Pedroso;T. Cubillas;E. S. Duria;D. Hess;I. Rams;A. Gutierrez;P. Kiès;N. Muniz;M. Pall;C. Pappas;D. Finkelstein;A. Patz;D. Rytel;J. Belt;D. Cain;A. Hillis
OBJECTIVES To evaluate panretinal photocoagulation for ischemic central vein occlusion and macular grid-pattern photocoagulation for macular edema with reduced visual acuity due to central vein occlusion and to further define the natural history of central vein occlusion. DESIGN A multicenter randomized controlled clinical trial supported by the National Eye Institute, Bethesda, Md. PATIENTS A total of 728 eyes from 725 patients were entered into one or more of four study groups: perfused, nonperfused, indeterminate perfusion, and macular edema. RESULTS Follow-up of study patients is still in progress and no results are available for the randomized groups (nonperfused and macular edema). Thirty-eight (83%) of 46 evaluable eyes in the indeterminate group eventually demonstrated at least 10 disc areas of nonperfusion (28 eyes) or developed iris and/or angle neovascularization before retinal status could be determined (10 eyes). Four-month follow-up information is available for 522 of the 547 eyes in the perfused group. Thirty of these 522 eyes demonstrated iris and/or angle neovascularization at or before the 4-month follow-up visit. An additional 51 eyes had developed evidence of at least 10 disc areas of nonperfusion by the time of the 4-month visit. CONCLUSIONS These findings confirm the importance of frequent follow-up examinations, including undilated slit-lamp examination of the iris, and gonioscopy in the management of all patients with recent onset of central vein occlusion.